Welcome to Flow Pharma Inc.

Page Loading...

Menu

FLOVID-20

Under Development, FDA Approval Required

A Targeted T-cell Immunotherapy for COVID-19 positive patients administered by your doctor using a standard inhalation nebulizer. FLOVID-20 is being developed for patients recently exposed to SARS-CoV-2 who are at risk of developing the COVID-19 disease.

by Flow Pharma, Inc., a California BioPharma Corporation
Ebola Vaccine Creator
United States Department of Defense Contractor
COVID-19 Public-Private Partnership Participant


Learn More

Forget the Needle

And forget the refrigerator. One and done.

An inexpensive powder, stable at room temperature.


Learn More

Seeing is Believing

FLOVID-20 showed efficacy in a pre-clinical study in non-human primates, protecting against COVID-19 pneumonia.


Learn More

Available & Scalable

Currently produced and rapidly scalable.

An innovative, inexpensive, COVID-19 treatment.


Learn More
blob-1
blob-2
Our Mission

Flow Pharma engineers and manufactures state-of-the-art biomedicines.

Our unique patented delivery systems and biotechnology are ideally suited for curative intervention in COVID-19, Ebola, and treatment-resistant cancers.


Our Biomedicines


FLOVID-20

COVID-19

A prophylactic needle-free nebulizer treatment to prevent COVID-19 in both virus-exposed and healthy patient populations. A unique targeted T-Cell immunotherapy biomedicine designed to help cure and prevent COVID-19.

FlowVax Ebola

Ebola

By relying on T-cells rather than antibodies, FlowVax Ebola provides long lasting protection through enhanced immune targeting and surveillance of the hidden Ebola virus nucleocapsid protein. FLOVID-20 targets the SARS-CoV-2 virus in the same way.

FlowVax Marburg

Marburg

Marburg is an Ebola-like virus suitable for weaponization by hostile forces. Working directly with the United States Dept. of Defense, we are developing FlowVax Marburg, a prophylactic nebulized biomedicine to protect at-risk military forces and civilians.

FlowVax BreastCA

Cancer

A revolutionary approach to breast cancer that utilizes T-cell biomedicines to provide highly efficacious therapy.

Our Medicine

All COVID-19 patients​
deserve meaningful treatment.

Efficacy, Safety, and Convenience are everything. We believe FLOVID-20 can provide it.

Under Development, FDA Approval Required

  • benefit-icon-0

    Efficacy

    designed to reduce hospitalizations and deaths

  • benefit-icon-1

    Safety

    using components currently used in FDA approved medications with no observed adverse events in our pre-clinical studies

  • benefit-icon-2

    Convenience

    inhaled, office-administered, inexpensive, hospital-free​